CO5570661A2 - Combinaciones que comprenden inhibidores de cox-2 y aspirina - Google Patents
Combinaciones que comprenden inhibidores de cox-2 y aspirinaInfo
- Publication number
- CO5570661A2 CO5570661A2 CO04034535A CO04034535A CO5570661A2 CO 5570661 A2 CO5570661 A2 CO 5570661A2 CO 04034535 A CO04034535 A CO 04034535A CO 04034535 A CO04034535 A CO 04034535A CO 5570661 A2 CO5570661 A2 CO 5570661A2
- Authority
- CO
- Colombia
- Prior art keywords
- cox
- aspirin
- dose
- inhibitor
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una composición farmacéutica para el tratamiento de condiciones en mamíferos, que son sensibles a inhibición de COX-2, que comprende en combinación una cantidad efectiva de un inhibidor de COX-2 y aspirina a dosis baja, para uso simultáneo, secuencial o separado.2.- El uso de un inhibidor de COX-2 para la preparación de un medicamento, para uso en combinación con aspirina a dosis baja para el tratamiento de condiciones en mamíferos que son sensibles a la inhibición de COX-2.3.- Un método para tratar un paciente que sufre de una condición que es sensible a inhibición de COX-2, que comprende administrar al paciente una cantidad efectiva de un inhibidor de COX-2 en combinación con aspirina a dosis baja.4.- El uso de aspirina a dosis baja para tratar síndrome de isquemia coronaria, trombosis, tromboembolismo, oclusión trombótica y reoclusión, ataque isquémico transitorio, y primero o subsecuente ataque trombótico, en un paciente que tiene la condición, cuando la aspirina a dosis baja se administra en combinación con una cantidad efectiva de un inhibidor de COX-2.5.- Una composición de acuerdo con la reivindicación 1, en donde la dosis de aspirina es una dosis en el rango de aproximadamente 70 mg a aproximadamente 10 mg o menos (por ejemplo al menos aproximadamente 5 mg) por día.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124459.9A GB0124459D0 (en) | 2001-10-11 | 2001-10-11 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570661A2 true CO5570661A2 (es) | 2005-10-31 |
Family
ID=9923664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04034535A CO5570661A2 (es) | 2001-10-11 | 2004-04-15 | Combinaciones que comprenden inhibidores de cox-2 y aspirina |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20040235802A1 (es) |
| EP (1) | EP1435968A1 (es) |
| JP (1) | JP2005505606A (es) |
| KR (1) | KR20040044891A (es) |
| CN (1) | CN1625405A (es) |
| AU (1) | AU2006249254A1 (es) |
| BR (1) | BR0213181A (es) |
| CA (1) | CA2458981A1 (es) |
| CO (1) | CO5570661A2 (es) |
| GB (1) | GB0124459D0 (es) |
| HU (1) | HUP0401854A2 (es) |
| IL (1) | IL160620A0 (es) |
| MX (1) | MXPA04003365A (es) |
| NO (1) | NO20041432L (es) |
| NZ (1) | NZ532158A (es) |
| PL (1) | PL369005A1 (es) |
| RU (1) | RU2004114560A (es) |
| WO (1) | WO2003033001A1 (es) |
| ZA (1) | ZA200401302B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US7338971B2 (en) | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
| WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
| JP2006501161A (ja) | 2002-06-11 | 2006-01-12 | ニトロメッド インク． | ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法 |
| CA2554332A1 (en) * | 2004-01-27 | 2005-08-04 | Merck Frosst Company | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
| EP1888045B1 (en) * | 2005-05-24 | 2010-09-08 | Flamel Technologies | Oral pharmaceutical composition for treating a cox-2 mediated condition |
| US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US20070043096A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Unit dose form with ibuprofen-famotidine admixture |
| US8067033B2 (en) * | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| EP2063873A2 (en) * | 2006-08-31 | 2009-06-03 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| CN104173359B (zh) * | 2014-09-05 | 2017-05-03 | 罗国安 | 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用 |
| WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
| US10272107B2 (en) * | 2017-09-05 | 2019-04-30 | Kenneth O. Russell | Method for treating inflammatory brain disorders and traumatic brain injury |
| US10586872B2 (en) * | 2018-07-03 | 2020-03-10 | International Business Machines Corporation | Formation of wrap-around-contact to reduce contact resistivity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743596A (en) * | 1987-06-16 | 1988-05-10 | Lapin Alfred R | Anti-arthritic preparation |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
| IL144763A0 (en) * | 1999-12-08 | 2002-06-30 | Pharmacia Corp | Valdecoxib compositions |
| GB0002336D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| US8680081B2 (en) * | 2000-08-29 | 2014-03-25 | Peter Van Patten | Prophylactic treatment of migraine |
-
2001
- 2001-10-11 GB GBGB0124459.9A patent/GB0124459D0/en not_active Ceased
-
2002
- 2002-10-10 PL PL02369005A patent/PL369005A1/xx not_active Application Discontinuation
- 2002-10-10 KR KR10-2004-7003586A patent/KR20040044891A/ko not_active Application Discontinuation
- 2002-10-10 JP JP2003535804A patent/JP2005505606A/ja active Pending
- 2002-10-10 MX MXPA04003365A patent/MXPA04003365A/es unknown
- 2002-10-10 RU RU2004114560/15A patent/RU2004114560A/ru not_active Application Discontinuation
- 2002-10-10 BR BR0213181-1A patent/BR0213181A/pt not_active IP Right Cessation
- 2002-10-10 WO PCT/EP2002/011380 patent/WO2003033001A1/en not_active Application Discontinuation
- 2002-10-10 CA CA002458981A patent/CA2458981A1/en not_active Abandoned
- 2002-10-10 EP EP02779476A patent/EP1435968A1/en not_active Withdrawn
- 2002-10-10 NZ NZ532158A patent/NZ532158A/en unknown
- 2002-10-10 US US10/487,759 patent/US20040235802A1/en not_active Abandoned
- 2002-10-10 CN CNA028200853A patent/CN1625405A/zh active Pending
- 2002-10-10 HU HU0401854A patent/HUP0401854A2/hu unknown
- 2002-10-10 IL IL16062002A patent/IL160620A0/xx unknown
-
2004
- 2004-02-18 ZA ZA200401302A patent/ZA200401302B/xx unknown
- 2004-04-05 NO NO20041432A patent/NO20041432L/no not_active Application Discontinuation
- 2004-04-15 CO CO04034535A patent/CO5570661A2/es not_active Application Discontinuation
-
2006
- 2006-12-08 AU AU2006249254A patent/AU2006249254A1/en not_active Abandoned
-
2007
- 2007-08-07 US US11/834,748 patent/US20080027032A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040044891A (ko) | 2004-05-31 |
| US20040235802A1 (en) | 2004-11-25 |
| US20080027032A1 (en) | 2008-01-31 |
| ZA200401302B (en) | 2005-01-04 |
| GB0124459D0 (en) | 2001-12-05 |
| CN1625405A (zh) | 2005-06-08 |
| MXPA04003365A (es) | 2004-07-23 |
| IL160620A0 (en) | 2004-07-25 |
| NO20041432D0 (no) | 2004-04-05 |
| WO2003033001A1 (en) | 2003-04-24 |
| HUP0401854A2 (hu) | 2004-12-28 |
| CA2458981A1 (en) | 2003-04-24 |
| PL369005A1 (en) | 2005-04-18 |
| JP2005505606A (ja) | 2005-02-24 |
| BR0213181A (pt) | 2004-08-31 |
| AU2006249254A1 (en) | 2007-01-04 |
| EP1435968A1 (en) | 2004-07-14 |
| NZ532158A (en) | 2006-04-28 |
| RU2004114560A (ru) | 2005-05-20 |
| NO20041432L (no) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
| BR0013704A (pt) | Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares | |
| EA200100870A1 (ru) | Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием | |
| SE9600072D0 (sv) | New oral formulation of two active ingredients II | |
| ES2144119T3 (es) | Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada. | |
| BR0008058A (pt) | Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada | |
| CL2012000348A1 (es) | Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica. | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| ATE377011T1 (de) | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer | |
| BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
| AR035533A1 (es) | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| BR0110877A (pt) | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer | |
| AR012671A1 (es) | Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos | |
| BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
| ES2098920T3 (es) | Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina. | |
| GT199900015A (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| BR0213293A (pt) | Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia | |
| AR015966A1 (es) | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito | |
| ES2126123T3 (es) | Empleo de cineol o mentol para el tratamiento de asma. | |
| DK0716611T3 (da) | Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt | |
| ATE505464T1 (de) | Feste form von amg 706 und pharmazeutische zusammensetzungen davon | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| HUP9801022A2 (hu) | Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására | |
| NO20042758L (no) | Fremgangsmate for behandling av en pasient som krever analgesi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |